Participated · Series A · Dec 2021

MFB Fertility, known commercially as Proov, develops at-home urine hormone tests—most notably a PdG test that measures a progesterone metabolite to confirm ovulation quality. The company received 510(k) clearance from the FDA for its PdG urine test in February 2020 and markets a suite of pregnancy-related hormone tests. Proov has rolled out a mobile app that uses machine-learning to score test-strip photos, provide ovulation scores, allow sharing with doctors, connect users with experts, and deliver lifestyle guidance. The company is developing a “complete” testing product that includes PdG, LH, FSH and an estrogen marker and is building an integrated supplement platform tied to the app. Proov has reported clinical-trial data (one unpublished trial of 54 pregnant women) suggesting PdG patterns may relate to miscarriage risk, though that data has not been peer reviewed or published. The company was founded in 2018 by CEO Amy Beckley and recently closed a Series A, indicating early-stage commercialization and growth funding.